Topic: Toll-like receptors
Idera touts higher response rate from the combo than Yervoy alone and a 76.5% disease control rate.
Soluble toll-like receptors could hold promise in reversing amyloid plaques.
A combination of Checkmate's TLR9 agonist and Merck's Keytruda reversed PD-1 resistance in melanoma patients.
French scientists discovered that an X chromosome-linked abundance of a toll-like receptor could be the root cause of lupus.
The 44% overall response rate in patients treated with IMO-2125 and Yervoy has emboldened Idera to move into phase 3 early next year.